65,437 trials
Irritable Bowel Syndrome
Primary: Subjects Who Experienced Relief of IBS Pain and Discomfort at Week 4 — 23; 18; 20 Participants
Metabolic Syndrome
Primary: C-reactive Protein (CRP) — 0.61; 0.68 Log10 mg/L — p=0.20
Glaucoma
Primary: Reduction From Baseline in Mean IOP at Week 12, Last Observation Carried Forward (LOCF) — 5.72; 7.18 mmHg
Cataract
Primary: Uncorrected Intermediate Visual Acuity — 0.771; 0.861 Decimal Visual Acuity
Cataract
Primary: Number of Participants That Achieved Best Corrected Distance Visual Acuity of 20/40 or Better in the First Eye. — 329; 114 Participants (First Eyes only)
Acute Otitis Media
Primary: Resolution of Otitis Media Symptoms — 14.2; 16.5; 7.5; 14.1 units on a scale — p=.002
Pregnant Women · Preeclampsia
Primary: Preeclampsia
Ulcerative Colitis
Primary: Induction Period (IP); Number of Participants With Clinical Response (Per Mayo Score) at Week 12: IP Cohort 1 (IP1C) — 30; 26; 14; 41 participants — p=0.124
Acne Vulgaris · Acne
Primary: Absolute Change From Baseline in Lesion Counts (Total, Inflammatory, and Non-inflammatory) at Week 12 (End of Study) — -15.5; -14.5; -13.9; -11.1 lesions — p=0.063
Cancer
Primary: Number of Patients Who Had Complete Response — 50; 42 participants — p=0.41
Cystic Fibrosis
Primary: Safety and Tolerability of Drug, Assessed by Change in Methemoglobin Levels — 0.4; 0.5; 0.3; 0.3 Percent of Methemoglobin Level
Refractive Error · Myopia
Primary: Limbal Hyperemia — 34.0967; 31.0920 units on a scale
Cigarette Smoking · Tobacco Use
Primary: Biochemically Confirmed 7-day Point Prevalence Abstinence From Tobacco — 5; 4; 0 participants — p=0.77
Myopia
Primary: Front Surface Lens Deposits — 0.68; 0.78; 0.77 Units on a Scale
Basal Cell Carcinoma · Squamous Cell Carcinoma
Primary: The Number of Subjects With Detectable Serum Lidocaine Concentrations (<0.1 ug/mL) at Each Blood Draw. — 0; 1; 0; 2 Participants